With B-IBD, I wonder if such a potent G+ antibiotic in the GI tract would upset the microbiome balance and have its own knock-on (medium term) AE's. What do you think as an MD? QOL improvement is a win, no doubt, but wouldn't BP and FDA be wondering this? I suspect follow-up of such effects will be examined in the upcoming oral IBD trial, which would be super-distal. Or would this be dismissed, given the accepted use of other potent oral ABX treatments?
News 
Market Data 
Discover 
